Is artificial leather a viable alternative?

Artificial leather is often marketed as a more sustainable option compared to traditional leather, yet questions remain about whether it truly delivers on this promise. Environmental concerns still surround the production of artificial leather, particularly the use of harmful chemicals in the process and its relatively limited durability over time.

Lab-Grown Leather, a subsidiary of BASF Enterprise PLC, has taken a unique approach to this challenge. Their focus is on creating leather through tissue engineering. By using immortalised cells, collected from an adult animal in a completely painless and ethically monitored procedure, they produce a structure similar to traditional leather, but grown entirely in a laboratory setting.

The lab-grown leather offers a cruelty-free and environmentally conscious solution, as it is derived from cultured animal cells. This innovative material provides several benefits. It is more sustainable, with a reduced environmental footprint and ethically sourced materials. In terms of durability, it retains the strength and wear-resistance of traditional leather, yet without the need for animal harm. Furthermore, the material’s versatility allows it to be tailored to suit different design and performance requirements, making it adaptable for a range of applications.

The idea of lab-grown leather opens up a conversation about the future of fashion. How could this emerging material revolutionise brands and play a role in creating a more sustainable industry?

Lab-grown leather presents a promising alternative that addresses some of the concerns associated with both artificial and traditional leather, offering an ethical and eco-friendly choice for the fashion industry.

BSF Enterprise plc (LON:BSFA), the owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues, is unlocking the next generation of biotech solutions. It is achieving this through an acquisition-led growth strategy to drive the development of lab-grown tissues.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
BSF Enterprise plc

More articles like this

BSF Enterprise plc

The potential of cultivated meat in advancing sustainability

As COP 29 unfolds, there is growing hope that cultivated meat may finally gain the essential financial and regulatory support needed to achieve scalability and commercial success. Che Connon, managing director of BSF Enterprise and CEO

BSF Enterprise plc

Breakthrough in corneal regenerative therapies

Kerato’s innovative “biosynthetic cornea” provides a promising alternative to traditional donor corneal transplants. Designed for one-time use, this injectable device is administered single-handedly. It forms a self-sealing gel in the eye, which reduces inflammation, promotes tissue

BSF Enterprise plc

BSF Enterprise achieves Global Certification for Quality Management

BSF Enterprise, along with its subsidiaries, has recently achieved ISO 9001 certification, a globally recognised standard for quality management systems. This accomplishment signifies a strong commitment to quality across all areas of the company, reinforcing its

BSF Enterprise plc

A new standard in cell culture care with CytoBoost

CytoBoost is a new, premium approach to cell culture, offering laboratories a way to enhance the health and performance of their cells. With this innovative product, you can think of CytoBoost as a dedicated solution designed

BSF Enterprise plc

UK’s opportunity to lead in cell-grown meat production

Europe’s approach to the agri-tech revolution is increasingly viewed as outdated, with its regulations often criticised as overly protectionist and wary of technological advancements. The continent’s approach to cell-grown meat production mirrors this attitude, with the

BSF Enterprise plc

Advances in corneal transplants in ophthalmology

The aging global population is driving a rise in vision impairment, which in turn affects physical, cognitive, and mental health. Among the most commonly transplanted human tissues worldwide are corneas, with approximately 185,000 procedures performed annually.

BSF Enterprise plc

UK biotech company expands production of lab-grown leather

A UK-based biotech company recently achieved a significant milestone by producing a larger size of cultivated skin tissue at its laboratory in Newcastle. The company, Lab-Grown Leather (LGL), formerly known as 3D Bio-Tissues, is owned by

BSF Enterprise plc

Cultivated meat and its potential

Cultivated meat, also known as cultured meat, is real animal meat produced by cultivating animal cells directly, removing the need for traditional animal farming. This meat is composed of the same cell types as conventional meat,

BSF Enterprise plc

BSF Enterprise making strong progress across portfolio of companies

BSF Enterprise PLC (LON:BSFA), the parent to a portfolio of innovative subsidiary companies developing cell-based tissue engineering solutions to deliver sustainable outcomes across a variety of sectors, has provided the following portfolio update. ●     Lab Grown Leather (LGL): Revolutionising

BSF Enterprise plc

Lab-Grown Leather expands sustainable leather production capacity

Lab-Grown Leather Ltd (LGL) has made a significant step forward by increasing its production capacity for lab-grown leather. This development highlights the potential of their technology to revolutionise the leather industry, providing a sustainable and ethical